Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety
- 15 April 2014
- journal article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 19 (6), 600-605
- https://doi.org/10.1111/1756-185x.12365
Abstract
To report the indications and safety of biologic agents in childhood rheumatic diseases at a tertiary hospital.Keywords
This publication has 26 references indexed in Scilit:
- Autoimmune-like syndromes during TNF blockade: does infection have a role?Nature Reviews Rheumatology, 2011
- Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritisClinical Rheumatology, 2011
- A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Annals Of The Rheumatic Diseases, 2010
- Biologics in children’s autoimmune disorders: efficacy and safetyEuropean Journal of Pediatrics, 2010
- Summary of worldwide pediatric malignancies reported after exposure to etanerceptPediatric Rheumatology, 2010
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009Annals Of The Rheumatic Diseases, 2009
- Switching biologic agents for uveitisEye, 2009
- Focus on adverse events of tumour necrosis factor blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patientsAnnals Of The Rheumatic Diseases, 2008
- Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritisAnnals Of The Rheumatic Diseases, 2008
- Tumor necrosis factor blockade in the management of children with orphan diseasesClinical Rheumatology, 2007